ImmunityBio, Inc. (NASDAQ:IBRX) Shares Purchased by Vanguard Group Inc.

Vanguard Group Inc. boosted its stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 2.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 17,328,229 shares of the company's stock after acquiring an additional 425,713 shares during the quarter. Vanguard Group Inc. owned 2.49% of ImmunityBio worth $44,360,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of IBRX. State Street Corp lifted its stake in shares of ImmunityBio by 10.1% in the 3rd quarter. State Street Corp now owns 8,654,460 shares of the company's stock valued at $32,195,000 after purchasing an additional 790,408 shares during the period. Clearwater Capital Advisors LLC raised its position in shares of ImmunityBio by 75.4% in the fourth quarter. Clearwater Capital Advisors LLC now owns 846,419 shares of the company's stock worth $2,167,000 after acquiring an additional 363,870 shares during the period. Barclays PLC increased its stake in shares of ImmunityBio by 127.4% in the 3rd quarter. Barclays PLC now owns 361,036 shares of the company's stock valued at $1,344,000 after purchasing an additional 202,248 shares in the last quarter. LPL Financial LLC raised its holdings in ImmunityBio by 67.2% in the 4th quarter. LPL Financial LLC now owns 257,449 shares of the company's stock worth $659,000 after purchasing an additional 103,495 shares during the period. Finally, XTX Topco Ltd boosted its position in ImmunityBio by 309.4% during the third quarter. XTX Topco Ltd now owns 92,910 shares of the company's stock worth $346,000 after purchasing an additional 70,215 shares in the last quarter. 8.58% of the stock is owned by institutional investors and hedge funds.

Remove Ads

ImmunityBio Stock Performance

IBRX traded down $0.11 during trading on Tuesday, hitting $2.78. The stock had a trading volume of 8,773,391 shares, compared to its average volume of 5,772,885. The firm has a market capitalization of $2.37 billion, a P/E ratio of -3.02 and a beta of 0.51. The company's 50-day moving average price is $3.01 and its 200 day moving average price is $3.53. ImmunityBio, Inc. has a twelve month low of $2.28 and a twelve month high of $10.53.

ImmunityBio (NASDAQ:IBRX - Get Free Report) last released its quarterly earnings results on Monday, March 3rd. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.26) by $0.11. The firm had revenue of $7.55 million during the quarter, compared to analyst estimates of $8.74 million. As a group, equities analysts expect that ImmunityBio, Inc. will post -0.92 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. HC Wainwright reissued a "buy" rating and issued a $8.00 price target on shares of ImmunityBio in a research note on Thursday, March 13th. D. Boral Capital reiterated a "buy" rating and issued a $30.00 price objective on shares of ImmunityBio in a report on Tuesday. Finally, BTIG Research initiated coverage on shares of ImmunityBio in a research report on Friday, January 10th. They set a "buy" rating and a $6.00 price objective for the company. One analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $12.19.

ImmunityBio Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.